Publication Name	World Journal of Gastroenterology
Manuscript ID	39372
Country	Italy

Received	2018-04-17 00:44
Peer-Review Started	2018-04-18 01:44
To Make the First Decision	2018-04-27 02:49
Return for Revision	2018-04-27 08:06
Revised	2018-05-06 17:29
Second Decision	2018-05-17 09:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-05-18 01:42
Articles in Press	2018-05-18 01:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-06-13 08:43
Publish the Manuscript Online	2018-06-15 09:13

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence
Manuscript Source	Unsolicited Manuscript
All Author List	Maria Lia Scribano
ORCID	Author(s) ORCID Number Maria Lia Scribano http://orcid.org/0000-0003-1839-8136
Funding Agency and Grant Number
Corresponding Author	Maria Lia Scribano, MD, Doctor, IBD Unit, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87, Rome 00152, Italy. marialiascribano@virgilio.it
Key Words	Vedolizumab; Crohn’s disease; Real-world; Efficacy; Ulcerative colitis; Controlled trial; Effectiveness; Safety
Core Tip	Vedolizumab represents an interesting new therapeutic option for the treatment of patients with moderate-to-severe ulcerative colitis and Crohn’s disease that are refractory or intolerant to either conventional treatments or anti-TNFα agents. This review describes the efficacy, safety, and tolerability of vedolizumab demonstrated in the clinical GEMINI trials. In addition, the paper reviews the effectiveness and the safety of vedolizumab in the real-world studies in order to identify its place in treatment algorithms for patients with inflammatory bowel disease.
Publish Date	2018-06-15 09:13
Citation	Scribano ML. Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467
URL	http://www.wjgnet.com/1007-9327/full/v24/i23/2457.htm
DOI	http://dx.doi.org/10.3748/wjg.v24.i23.2457

Full Article (PDF)	WJG-24-2457.pdf
Full Article (Word)	WJG-24-2457.doc
Manuscript File	39372-Review.docx
Answering Reviewers	39372-Answering reviewers.pdf
Audio Core Tip	39372-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	39372-Conflict-of-interest statement.pdf
Copyright License Agreement	39372-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	39372-Language certificate.pdf
Supplementary Material	39372-Supplementary-Material-revision.pdf
Peer-review Report	39372-Peer-review(s).pdf
Scientific Misconduct Check	39372-Scientific misconduct check.pdf
Scientific Editor Work List	39372-Scientific editor work list.pdf